



Trustees' Report and Financial Statements for Year Ended 31 December 2020

About This Report

The Trustees present their Annual Report including Strategic Report together with the audited Financial Statements of the group and the company for the year 1 January 2020 to 31 December 2020. The Annual Report serves the purpose of both a Trustees' Report and a Directors' Report under company law. The Trustees confirm that the Annual Report and Financial Statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Contents

About This Report	2
About the CCDC and Its Purpose	4
We Shape the Future	4
What We Do	4
What Makes Us Different?	5
Supporting the Community	5
Our Strategy: Advancing Structural Chemistry Worldwide	6
Our Strategic Aims in Line with Our Vision and Mission	7
Our Values	8
Diversity and Inclusion	8
Delivering Our Vision	10
Impact of the CCDC	12
The Crystal Structure Prediction Blind Test	13
CCDC Studentship Program	14
Key Product Releases	15
CSD-Core Updates	15
CSD-Discovery Updates	16
CSD-Materials Updates	17
Financial Review	18
Principle Funding	18
Expenditure	19
Investment Policy	20
Reserves	21
Structure, Management and Governance	22
Governance	23
Management and Staffing	25
Remuneration Policy	25
Risk Management	25
Going Concern	26
Looking into the Future	27
References and Administrative Details of the Charity, its Trustees and Advisors ..	29
Statement of Trustees' Responsibilities	30
Independent Auditor's Report	31
Consolidated Statement of Financial Activities	36
Consolidated Balance Sheet	37
Charity Balance Sheet	38
Consolidated Statement of Cash Flows	39
Notes to the Financial Statement	40

About the CCDC and Its Purpose

We Shape the Future

With scientific software and high-quality data services that accelerate the discovery and development of new medicines, chemical products and advanced materials.

By promoting collaboration across academia and industry globally to generate new discoveries in structural science.

By inspiring and training a new generation of structural chemists world-wide through outreach and education.

What We Do

CCDC are world-leading experts in structural chemistry data, scientific software and knowledge for materials and life science research and application.

We specialise in the collation, preservation and application of scientific structural data for use in pharmaceutical discovery and manufacturing, materials development and research and education.

We compile and distribute the Cambridge Structural Database (CSD), a certified trusted database of fully curated and enhanced organic and metal-organic high-quality structures, used by researchers across the globe.

Our cutting-edge scientific software empowers scientists and researchers to extract invaluable insights from the vast dataset, informing and accelerating their research and development.

Photograph of early CCDC scientists



What Makes Us Different?

High-quality trusted data

Each structure within the CSD undergoes extensive validation and cross-checking via automated workflows (utilising machine learning) and through manual curation by our expert chemists and crystallographers. This means you can trust that all the data within the CSD is accurate, consistent and of highest quality.

Furthermore, we enrich all the data with bibliographic, chemical and physical property information, and a range of additional metadata, adding further value to the original structural data, enabling you (and machines) to interpret structures in a chemically meaningful way.

Unique data

We enable researchers to publish data that otherwise would have remained unpublished, confidential and unknown, directly through the CSD. The CSD therefore contains data that isn't available anywhere else in the world.

Intelligent software and expertise

Our in-house software experts keep up to date with the latest developments in global data and software, applying their knowledge and expertise, to develop robust systems that provide researchers with the tools to access, search, visualise and meaningfully interpret the data within the CSD.


Knowledge

Using novel application of existing and new algorithms and methods to explore the high-quality structural data and physicochemical properties within the CSD, we are able to extract scientific insights to advance structural science worldwide.

Supporting the Community

We are committed to the advancement of chemistry for public benefit, serving the global chemistry community by helping to address our customers' structural, physical and chemical challenges through high-quality data, cutting edge software and specialist knowledge.

We offer a selection of products and services free of charge for the benefit of the scientific community. Our services cover a wide range of crystallographic tools — from data collection, validation and visualisation to teaching, research and analysis.



Refcode: OFIHET
DOI: [10.5517/ccdc.csd.
cc20l28z](https://doi.org/10.5517/ccdc.csd.cc20l28z)

Our Strategy: Advancing Structural Chemistry Worldwide

The main objective of the Charity is the general advancement and promotion of the science of chemistry and crystallography in all its branches for the public benefit.

The CCDC's strategy is to continue collecting, curating, making available and learning from structural chemistry data on a deeper but faster and more interlinked level and gradually more in line with open and FAIR (Findable, Accessible, Interoperable, Reusable) requirements, going from 1 million structures to 2 million+ over the next 5 years. Both more complex molecules (for example proteins, macromolecules, metal-organic frameworks, polymers) and non-experimental data or theoretically calculated data (for example crystal structure prediction landscapes, or structures with Density-functional theory recalculated

H-positions) will be stored. This data growth and extension to coverage and higher interlinkedness will be based on a new foundational database architecture presently evolving, which is much more scalable and future-proof.


Through updated editorial workflows and improved interactions with the wider scientific community and all depositors, we will capture and add more fields and metadata, as well as physicochemical data (such as melting points and solubility). We endeavour to lead structural scientific research by working with all our in-house scientists and the research partners and international academic network. By developing and supporting industry leading scientific software (CCDC's materials/particles/theory suite and discovery suite as well as the combined enterprise suite) and utilising all our underlying high-quality and high-precision data, we will create new insights by methodical knowledge exploration using novel techniques in artificial intelligence (AI)/ machine learning (ML)/ deep learning (DL). To this end the centre is building up a distributed and heterogeneous high-compute infrastructure, using all our existing computational power, and flexing this elastically into the wider cloud to address the necessary scientific computations.

Furthermore, enabling education and outreach on a global scale is essential and will help promote the power of structural science, and get the next generation of scientists trained up, thereby ensuring better adoption of CCDC's software suites and data within both academia and industry – building up future champions.

The 1 millionth structure in the CSD.

CSD Refcode: XOPCAJ

DOI: [10.5517/ccdc.csd.cc20vdhs](https://doi.org/10.5517/ccdc.csd.cc20vdhs)



Our Strategic Aims in Line with Our Vision and Mission



Collecting, curating, making available and learning from structural chemistry data

Be the world's most comprehensive and trustworthy repository of structural chemistry knowledge for life science and materials science research and application; establish the concept of data trust, and CCDC FAIR (Findable, Accessible, Interoperable, Reusable) / open access.



Leading structural scientific research

Be recognised by industry as the 'go-to' partner for structural science innovation (e.g. creation of digital drug design and manufacturing centres). Enabling world-class academic research that advances the application of structural knowledge via our growing global research network.



Creating new insights

New scientific insights based on exploration of high-quality structural data. Novel application of existing and new algorithms and methods (artificial intelligence, machine learning, deep learning, statistics, automation etc.).



Creating and supporting industry-leading software

Delivering a modern, cohesive and reliable software ecosystem (cloud-based) that enables our users to gain new insights from structural data.



Enabling education and outreach

Be the globally leading provider of structural chemistry information for use in education to promote the power of structural science.



Supporting our people

Living to our values, be a healthy, happy, collaborative, productive, innovative and fun place to be; working as teams, with drive, urgency, energy and pro-activity.



Customer centricity

Be customer-focused and deliver timely against requirements and on target.



Delivering sustainability

Generating sufficient funds to do what our community and customer-base (both industrial and academic) needs us to do.



Our Values

At CCDC our mission is to shape the future of structural science by accelerating the discovery and development of new medicines and chemical products.

We do this by promoting collaboration across academia and industry, and by inspiring a new generation of structural chemists globally through outreach and education.

We have nine core values underpinning everything we do to ensure we achieve our mission.

The CCDC and its staff live by the following nine principles and value statements, and over 2020 we have embedded this to a growing extent in the ways we work across the organisation, at all levels.

Diversity and Inclusion

During 2020 we created a Diversity and Inclusion Team. Membership of the team is made up of Board of Trustee Champions, the CEO, Head of HR and staff representative volunteers from across the CCDC and CCDC Inc.

The team's remit is to promote and champion diversity, inclusion and equality

both in the workplace and within our structural chemistry community. The first initiative of the team was to define a ninth core Value, Diversity, detailed above.

All staff also attended an event on Unconscious Bias explaining how we may unknowingly treat individuals and groups differently due to bias, and the effects that can have on behaviour and decision-making processes.

Work has commenced on identifying the areas the CCDC can act on with respect to Diversity and Inclusion, so we transform enthusiasm to action.

Public Benefits

The CCDC Board of Trustees holds in high regard the principle of public benefit and requires the CEO, wider senior leadership and staff of the CCDC to pursue policies that demonstrate this. The Board of Trustees, at its quarterly meetings, reviews ongoing charitable activities to ensure consistency with our charitable objects. The Board of Trustees is aware of the Charity Commission's guidance on public benefit and has had regard to it in determining the Charity's aims and objectives and in the way it carries out its activities.

Photograph to celebrate 'Women in Science' day 2020





Community

We serve the global scientific communities for the public benefit.



Collaboration

We work together and engage positively with others to achieve our goals.




Customer Centricity

We work together and engage positively with others to achieve our goals.



Integrity

We act with integrity and communicate honestly and transparently.



Innovation

We push boundaries in all that we do and creatively advance understanding.



Passion

We are enthusiastic about the services we provide and committed to the people we help.



Quality

We are experts in our field, producing trusted resources for our community and customers.



Agility

We act in flexible and efficient ways, with a sense of urgency and turn around requests as fast as possible without compromise to quality.



Diversity

We believe in diversity and inclusion, and we work to create a culture of belonging, where everyone is welcome, valued and respected.

Delivering Our Vision

During 2020 the Cambridge Structural Database (CSD) grew to **1,097,619** entries and **1,076,290** unique structures. This was an increase of over **63,000** entries in 2020 and an additional 35,000 existing entries were improved and enhanced through our annual CSD Improvements programme. During the year four data releases were delivered through our desktop software and users could access up-to-the-minute data updates through our online services such as Access structures and WebCSD.


The CSD continues to be a global community resource and in 2020 alone deposited structures were determined by over 5,500 different crystallographers from over 85 different countries. The growth of the CSD was impacted by the pandemic and the closure of laboratories worldwide with the growth of the CSD slightly lower than expected at the outset. However, despite this the number of new entries added in 2020 was comparable to previous years. The ability for researchers to publish directly through the CSD for free as CSD Communications helped support the amount of new crystal structures shared with the community.


CSD Communications continued to be the number one way to share structural data with over 5,000 additional structures shared during the year.

A number of articles continued to highlight the value of 1 million+ crystal structures, including a themed collection in CrystEngComm: ["The Cambridge Structural Database - A wealth of knowledge gained from a million structures"](#). This special issue contained 33 papers from academia and industry highlighting the breadth of applications made possible with this data.

Although the pandemic meant many events and conferences were cancelled, the CCDC continued to support the global scientific community virtually. We participated in a number of virtual international conferences including the [Fall 2020 American Chemical Society](#), and [3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry](#). Alongside participating in international conferences, the CCDC hosted several fully virtual User Group Meetings and a Science Day.

Chart showing the growth of the CSD up until the end of 2020





Map showing where people registered from for our three CCDC Virtual Workshops and the two training schools the CCDC were involved with in Q4 2020


2020 also saw us recruit a new Education and Outreach Officer (E&O) who enabled us to expand the E&O activities of the centre.

During 2020, the CCDC hosted three free virtual workshops and delivered training at two international crystallography schools. In total we had over 200 attendees at the virtual training sessions with attendees logging on from over 45 different countries. These events also enabled the promotion of our Frank H. Allen International Research and Education (FAIRE) programme that provides free access to the CSD and associated software to scientists in developing countries.

In 2020 alone over 17 peer-reviewed research articles were published because of our FAIRE programme, this is up from over 11 in 2019 and takes the total number of publications that have been made possible through FAIRE to over 60.

As well as supporting and hosting virtual global events, the CCDC established and enriched the educational resources we provide.

These resources include guided step-by-step workshops, how-to videos and social media software tips to help users explore the CSD and associated software. 2020 also saw the CCDC take on the hosting of DECOR (Database of Educational Crystallographic Online Resources), a collection of teaching material designed to support educators in teaching crystallography. For younger aspiring scientists, we developed the CCDC Home Learning collection, which comprises of a handful of fun activities to introduce children to the wonders of crystals.




Impact of the CCDC

Our data, software and services are used extensively both for industrial research and for academic endeavour. Users have published some 2,612 papers with a topic of "Cambridge Structural Database" since 1984, according to Web of Science. As can be seen from the histogram, the numbers of publications that cite the CSD as their topic of research have steadily increased since the year 2000.

The impact of the CSD is truly global. Web of Science shows that publications with the CSD as a topic have emerged from 87 countries worldwide, shown in the map visualisation below.

Finally, the CSD has a broad impact in 59 different topic areas. Those where more




Growth in publication with the CSD as their topic of research in Web of Science

than 100 papers exist are shown below. We note that while the high-ranking topics are dominated by chemistry and crystallography, the range of themes covered is far higher, for example, single papers have been published in areas such as toxicology or forensic analysis.



Map showing the countries that publish papers based on the CSD




Pie Chart showing the common Web of Science categories

The Crystal Structure Prediction Blind Test

Crystal Structure Prediction (CSP) is a key scientific endeavour. The end goal of crystal structure prediction is to predict reliably all the crystalline forms that a compound can form starting from the 2D chemical diagram. CCDC has run a series of high-profile benchmarks of crystal structure prediction over the past 22 years. Rather like the Critical Assessment of Structure Prediction (CASP) protein folding tests, the CCDC CSP blind test challenges methods developers to predict unknown structures. Google DeepMind caused a stir at the recent CASP test by achieving significant improvements to the results obtained due to methodological advances. We've seen more incremental improvements in CSP since 1999, with groups steadily achieving more success each time the test has been run. In some ways, predicting a crystal structure is considerably harder than a test of protein folding; the required degree of accuracy is an order of magnitude higher in CSP for a prediction to be useful, and in CSP the range of chemistries that need prediction is far broader than the chemistry of polypeptides.


The process of the blind test is visualized in the figure. Initially, CCDC sources a set of compounds with crystal structures. These structures are held back from deposition in the CSD and kept blind at CCDC. Participants are then set the challenge of predicting these structures. They submit their predictions to the team at CCDC who assess the results and present them back to the participants and summarise the overall achievements of the teams in a post-test meeting and paper.


We launched the latest test in October 2020 (7th blind test). The test has 7 systems. 3 are deemed methods development systems, whilst 4 are aimed specifically



Visualisation of the blind test

at the agrochemical and pharmaceutical industries. So far, 42 teams have registered an interest in taking part. If all these teams submit entries, we will have 14 more groups involved in the test this time around. This up-tick in participation is to be expected. Interest in the blind test mirrors the growing interest in CSP across the pharmaceutical industry; more parties are interested in using CSP commercially and consequently more groups are actively interested in developing new methods.





CCDC Studentship Program

The CCDC runs a vibrant and varied studentship programme. Typically, CCDC aims to start 3 PhDs during a given year, though in 2020, due to late starting from the previous year, 6 new students started out across institutions in the UK. Typically, 9-12 students are in train at any one time. Currently we have 15 students active; this is higher due to COVID-19, which has prevented some students from completing PhDs due to a lack of access caused by lab closures. The historical network of European PhDs is shown below, colour coded by institution. The circle size indicates the degree of activity with the institute, vis-a-vis the number of students who have been hosted at the institute through time.


We have also had PhD students based in the USA historically. Currently we only have students in the UK, but we are looking to expand our network in the coming years to include other countries. The students study in a wide variety

Map showing the historical network of European PhDs. Colour coded by institution.

of topic areas. For example, this year we have had new projects starting in materials science, artificial intelligence for drug discovery and in characterisation of metal-organic frameworks.



Key Product Releases



2020 saw several significant releases across the CCDC Product Portfolio, with three major desktop releases, along with two maintenance desktop releases, plus three smaller releases of additional or web-based components.

Across these releases, we continued to focus on the needs of our various user communities and worked harder on user experience throughout the portfolio.

Alongside these releases, we spent a significant amount of time and effort working on the foundations of the platform that will underpin our whole CCDC Product Portfolio into the future—the database, architecture and user experience (UX). The impact of much of the progress on the database and architecture will start to be felt in 2021, but the clear architectural vision has already helped a lot over 2020, as has a much stronger focus on UX throughout 2020.

In 2021, our product releases will continue to build on this progress over 2020 through our evolving product roadmap – you can see a visual overview of the product roadmap above.

Overview of the CCDC Product Portfolio Roadmap across all areas.

CSD-Core Updates

In 2020 we re-launched our foundational product suite within the CCDC Product Portfolio as “CSD-Core”, retiring the previous name of “CSD-System”. This change in name emphasises the nature of the suite as the heart of our portfolio, providing core capabilities that are of relevance to all areas of structural science, all the way from chemistry and physics through to biology. The CSD-Discovery and CSD-Materials suites are focused on specific application areas, but the functionality within CSD-Core is of relevance to all structural science applications including fundamental structural research, pharmaceuticals, agrochemicals, energetic materials, paints, pigments, dyes, organic semiconductors, non-linear optics, ferroelectrics, magnetic materials, catalysts, gas storage materials, batteries and many more. This re-branding also coincided with now including Hermes in the CSD-Core suite to cover core protein visualisation capabilities and extending IsoStar to cover a range of new functional groups.

2020 saw us developing component collections for two of the major pipelining tools to make the CSD data and CCDC scientific tools available to researchers in the pharmaceutical and agrochemical industries for integration within their scientific and enterprise workflows. We launched the first CSD Pipeline Pilot component collection as well as the first CSD KNIME (Konstanz Information Miner) component collection. Both collections include components for core tasks, such as access and search of CSD data.


CSD-Discovery Updates

Building on the new workflow capabilities (Pipeline Pilot and KNIME) released to our CSD-Core users in 2020, users of CSD-Discovery will also be able to run GOLD (Genetic optimisation for Ligand Docking) docking calculations including Ligand preparation (from SMILES) via KNIME or perform ligand-based virtual screening and conformer generation via Pipeline Pilot.


We also enhanced the capability of our GOLD software for Ultra Large docking with improved security compared to previous versions. This was supported by the publication of a white paper illustrating an exemplar docking run of about 130 million compounds against a chosen protein structure, using GOLD deployed onto cloud-based computing resources.

Other achievements for the CSD-Discovery community include the funding award from the BBSRC's Bioinformatics and Biological Resources Fund, for a project that will see the integration of structural, functional and biochemical data across small molecules and macromolecules. The initiative, called BioChemGRAPH, will bring together data from the Protein Data Bank in Europe Knowledge Base (PDBe-KB), ChEMBL and the Cambridge Structural Database (CSD).

Overview of the CCDC Product Portfolio, including the renamed CSD-Core suite at the heart



Applications within the CSD-Discovery suite




CSD-Materials Updates

2020 saw us release two new components to Crystal Form Consortium (CFC) members and Research Partners, these were our Solvate Prediction and Crystallisability Prediction components, built using machine learning approaches, aiming to address the needs of experimental solid form scientists. These components focus on information that can be gained in the absence of 3D structural data.

We also launched the Aromatics Analyser component to the wider CSD-Materials community in early 2020, allowing them to assess the number and relative strength of interactions between aromatic functional groups in their small molecule structures. Alongside this, we launched a collection of molecular descriptors which can be accessed through the CSD Python API which will allow users to utilise these in their own machine learning model-building utilising the CSD.

Our annual CFC meeting was transitioned to a half-day virtual event in April 2020, this allowed us to communicate our latest research on aromatic interactions and the science and development behind the new Solvate and Crystallisability Prediction components released to these users in May 2020.





Applications within the CSD-Materials suite

2020 also saw us drive engagement with Crystal Structure Prediction (CSP) users within pharmaceutical organisations to build a platform to store and visualise CSP energy landscapes in a structured, searchable way to enhance the utility from the increasing volumes of CSP data that will be generated in the future.

Other key achievements within the Materials Science team include CCDC involvement in the Digital Design Accelerator grant from InnovateUK, allowing us to work with leading UK academics and UK based pharmaceutical organisations to connect material design to product performance for formulated products. This two-year collaboration began in March 2020 and has facilitated research and product development towards delivering a Particle Informatics workflow. We were also successful in securing a 34-month Knowledge Transfer Partnership (KTP) with the University of Leeds to develop a commercial implementation of an academic tool built by the School of Chemical and Process Engineering at Leeds to further strengthen our approaches to supporting digital design for drug development and manufacturing.

Refcode: ABECES
DOI: [10.5517/ccdc.csd.cc1m68kn](https://doi.org/10.5517/ccdc.csd.cc1m68kn)

Financial Review




Principle Funding

The CCDC's principal funds arise from the subscription fee to the Cambridge Structural Database and its associated applications. Its subscribers are academic research institutions and industrial companies. The annual contributions requested from the worldwide academic community are significantly discounted from the industrial levels, in particular for users from less wealthy nations. Income from academic institutions is set at a level required just to maintain the CSD data content. Income from non-academic users meets the costs of developing the database and related software, enables the CCDC to invest in relevant scientific methods and applications' research and development. The CCDC received government grants for specific projects during 2020. It also received donations from its trading subsidiary CCDC Services Ltd under a Deed of Covenant. The CCDC holds an investment portfolio from which it receives dividends. The charity does not seek to raise funds from third parties by way of donations.

Despite the pandemic, CCDC's performance continued to be strong. Driven by a strengthened Business Development team, we achieved a 9% growth compared to prior year. The total

A breakdown of the revenue for 2020

revenue was £7,167,530 (2019: £6,584,373). We have added 47 new subscribers, while retaining over 90% of the existing users.




Graph showing the growth in revenue from 2019 to 2020

Expenditure

The activities undertaken in the year were carried out within the budget approved by the Trustees, and all the expenditures were spent for charitable purpose.

The total expenditure in 2020 was £6,629,236 a decrease of 12% on 2019 (£7,495,242).

A breakdown of the expenditure for 2020




The chart above shows a 13% decrease in Direct Costs and an 18% decrease in Support Costs, but a 222% increase in Grants.


Staff costs remain the largest expenditure for the CCDC. The net change in the total staff number increased from 72 to 79, between 1 January and 31 December 2020. Total staff costs in 2020 were £5,118,289 (2019: £5,563,083). This is an 8% decrease from the previous year despite the increase in headcount. This is due to a large adjustment (£1,149,888) made to the University Superannuation Scheme (USS) pension provision in 2019, while in 2020 the adjustment was £111,338. USS

is a multi-employer defined benefit scheme in which most of CCDC's staff participate. CCDC is making an additional contribution to address the funding deficit of the scheme.

The costs in maintaining scientific equipment increased to £263,750 (2019: £206,555). Cloud costs increased in 2020 to support several Microsoft Azure based projects including Licensing, Database Evolution and Gold Docking. Remote working and additional marketing efforts led to an increase in spending on communication, marketing and collaborative working tools. We are confident that these investments will improve operational efficiency, meet the demand of our users by providing a flexible licensing system and enable us to reach out to potential users more widely. These investments follow our digital transformation theme and are made to enable future growth. To support working from home, we spent an extra £25k on computer and office equipment and together with a network upgrade to 10Gb we have enabled greater flexibility for remote/hybrid workers.

We spent £200,052 on the premises in 2020, £55k less than the previous year, as the major building improvement work was completed in 2019. The building was largely unoccupied during the first lockdown. Minimum number of staff returned to the office on occasions after the restrictions were eased in the summer. The costs on utilities were significantly reduced. However, in line with Government guidance, we have spent extra £15k on making the building Covid safe for staff to return as and when it is permitted.





The most noticeable reduction in costs was on Attendance at Scientific Meetings due to global travel restrictions. We quickly adapted to the changing environment and moved workshops, User Group Meetings, Consortium meetings etc. online. In 2020, £32,116 were spent compared to £247,380 in 2019, a saving of £215,264.

While Direct Costs and Support Costs were reduced, the Grants we made to support PhD studies increased from £75,645 to £243,337. During the year, we made new commitments to 7 universities to sponsor research in a wide range of topics. We also extended our support for the students whose studies were affected and prolonged by the pandemic. Currently we have 15 students studying with us.

The CCDC holds an investment portfolio which was affected by the performance of global market. It produced an unrealised loss of £31,800 (2019: gain £803,157). This brought the overall financial performance of the CCDC to a surplus of £506,494 in 2020 (2019: deficit of £107,712).

Investment Policy

Since 1987, CCDC has looked to build up its reserves to provide financial stability and to enable it to fund its research and development activities. The primary objective of the investment policy is to preserve the capital and income in the investment portfolio from inflation.

In 2015, the Board of Trustees reviewed the investment policy. As a result, Newton Investment Management Ltd were appointed as our investment managers and the monies were moved from the incumbent Investment Manager and invested into Newton Growth and Income Fund for Charities.

The investment policy sets no specific ethical constraints on the investment portfolio. However, the portfolio should be invested in a socially responsible manner and the investment manager of the portfolio is expected to consider environmental, social and governance (ESG) issues in their investment analysis and decision-making process, engaging with company management where appropriate.

It is the practice that the investment advisers attend regular meetings of the Board of Trustees and report on the progress of the fund, and of the CCDC's investment into it. Detailed written reports are produced on a quarterly basis which value the portfolio and record its

The fund's performance in the last 5 years.

Fund performance calendar years %

	2020	2019	2018	2017	2016
Newton Growth and Income Fund for Charities - Net	1.55	18.34	-1.08	13.14	13.81
Newton Growth and Income Fund for Charities - Gross	2.16	19.05	-0.49	13.82	14.49
Performance Benchmark	1.06	16.72	-5.06	10.21	17.90

respective performance statistics. An integral part of the regular meetings is a detailed discussion on the content of the report with particular reference to the performance aspect. The table shows the fund's performance in the last 5 years.

The Executive Team at the CCDC review monthly reports from the investment managers. The Trustees will review the performance of the investment portfolio on a half-yearly basis. A more formal independent review of the investment manager and investment policy will be carried out at least every five years or more frequently if the circumstances require. An independent review was carried out during 2020. The Board were satisfied with the performance of Newton Growth & Income Fund for Charities. It was decided to continue investing with Newton.

The global market performance was heavily affected by the pandemic. It fell sharply in Q1. It has since recovered steadily influenced by the encouraging vaccine news. At the end of the year, the value of the portfolio stood at £5,924,609, which represented an unrealised loss of £31,800. CCDC's strategy is investing for the long term. No withdrawal or deposit was made in 2020. During the year, we received £116,960 investment income which was not reinvested (2019: £161,174).

Reserves

CCDC's Reserves Policy is to maintain sufficient levels of reserves to enable normal operating activities to continue over a period of at least six months should a shortfall in income occur; the policy should take account of potential risks and contingencies that may arise from time to time. CCDC's reserves policy requires

the retention of income sufficient to encompass:

- The balance on tangible and intangible fixed assets for use by the Charity to avoid having to liquidate functional assets to release cash less all loans associated directly with these assets.
- To cover 50% of the direct costs and support costs, agreed in the budget or at meetings of the Board of Trustees.
- Funds to enable designated expenses and provisions which are anticipated to be greater than £200,000 less any external funding of them.
- The reserves policy is reviewed annually to take into consideration perceived risks and opportunities.

At the end of 2020, CCDC's free reserve was £4,427k (2019: £4,491k), it is sufficient to cover 50% of the 2021 budgeted expenditure of £4,163k.

Our present position is:

	31 Dec 2020
Unrestricted Reserves	£7,545,444
Designated Funds	
Fixed Assets Fund	£2,024,755
Research and Development Fund	£173,406
Sponsorship and Outreach Fund	£76,000
Pension Provision Fund	£744,000
Sustainability Fund	£100,086
Free Reserves	£4,427,197
2021 Budget cost -50%	£4,163,000

Structure, Management and Governance

CCDC was incorporated as a Company Limited by Guarantee on 18 August 1987. It has no share capital and is a registered charity. The guarantee of each member is £1. The governing documents are the Articles of Association of the company (as amended May 2010).

In addition to CCDC, the Charity operates the following subsidiaries:

CCDC Services Ltd. (formerly CCDC Software Ltd.)

A wholly owned trading subsidiary of the CCDC. It was established in 1998 to deliver bespoke software development as necessary to meet the requirements of CCDC's charitable status. Since 2015, its trading activities have evolved towards professional services from software development. 2019 was the first year when all its revenues arose from professional services (includes Digital Drug Design and Manufacturing Centres). The CCDC's Board of Trustees and the Director of CCDC Software Ltd. approved of the name change to best reflect the trading activities of the company in May 2019. The name change was officially registered with Companies House on 28 July 2019. The company is located at the same address as CCDC. The Directors of CCDC Services Limited are the Chair of the Board of Trustees and the Chief Executive Officer of the CCDC. The Directors meet at least once a year.

CCDC Inc.

Established 9 September 2013 as a New Jersey company. CCDC Inc. is a standard US Corporation, wholly owned by the CCDC, whose Directors include a Trustee of the CCDC who does not receive remuneration, and two external Non-Executive Directors with an annual remuneration of \$5,000. Day-to-day management has been delegated to the General Manager. CCDC Inc. was established to provide scientific and technical services to the CCDC user communities across the Americas, which represents almost 40% of the worldwide total revenues. All legal and other agreements with users remain with the CCDC and CCDC Services Limited. The Directors meet once a year, usually in April.

An office was originally established within University of Rutgers, at the Center for Integrative Proteomics Research. As we continue to grow our US user community, we believe the needs of our users can be better served by retaining a core sales and support team in a virtual office to provide the rapid response they demand. This would also allow flexibility to locate US staff closer to the user community. A virtual office was established in July 2018. CCDC Inc's staff are located across the US.

CCDC All Staff photograph 2019



Starting from 1 January 2020, CCDC Inc. has a business office address at 1 International Place, Suite 1400, Boston, MA 02110, USA. It has since moved to 1 Boston Place, Suite 2600, Boston, MA 02108, USA. It provides conferencing facilities and other administrative services.

Governance

The Charity is governed by the Board of Trustees who delegate operational management to the Chief Executive Officer (CEO), supported by an Executive Leadership Team (ELT) covering all functions of the organisation, as well as a newly established Wider Management Team (XMT), the Operational Management Team (OMT), Product Management Board (PMB), Technical Review Board (TRB) and Knowledge Management Team (KMT). Other cross-functional teams or groups such as change management exist. Over 2020 the senior leadership team was called SLMT. The organisational structure was then optimised further over Q4, and we have now put in place an ELT, as well as other improvements to the functions of the CCDC (and adding a combined operational function).


In accordance with governing documents, potential Trustees are appointed by the Board based on recommendations by the Nominations Committee of their specific skills, location, and diversity. Potential Trustees are sent an induction pack covering their obligations under Charity and Company Law; Articles of Association; Memorandum of Association and Codes of Practice; company policies and a non-disclosure agreement. Potential Trustees are invited to attend Board meetings as observers following which the Board of Trustees and the individual consider their suitability to act as a Trustee ahead of their formal acceptance to the post, at the Annual General Meeting (AGM). Upon acceptance and appointment, Trustees receive an induction to the business, covering key aspects of the organisation,

its operations and salient Health and Safety information.

The Board of Trustees usually meets at the CCDC twice per annum in May and November, with two further virtual meetings in February and August. Due to the pandemic all Board meetings were held virtually during 2020. Working to a standing agenda, the meetings with the CEO and the ELT provide oversight on the performance and progress of the Charity in line with strategy. Progress reports from all functions are presented to the Board at these meetings. In addition, the Board also receives monthly management account reports, which includes the investment performance and cash balances. The opportunity for all staff to interact with the Trustees is encouraged at all times and pre-COVID-19 was specifically addressed as part of the on-site meetings. As soon as the restrictions on travel are relaxed these interactions will resume.

In addition to the Board meetings, the Board members hold regular, four-weekly, telephone update calls with the CEO to address any matters arising from the meetings in a timely manner and to pick up on any issues that need action or to generally discuss trends, and any matters of interest to the advancement of the Charity.

During 2020, meetings of the Board committees, Nomination, Audit, Risk and Remuneration were established and added to the corporate calendar in accordance with their terms of reference.





Nomination Committee

The purpose of the Nominations Committee is primarily to ensure that:

- The Board and its committees should have the appropriate balance of skills, experience, independence and knowledge of CCDC to enable them to discharge their respective duties and responsibilities effectively.
- There should be a formal, rigorous and transparent procedure for the appointment of new trustees to the Board of CCDC.
- There should be an efficient, fair and thorough process on which the Nominations Committee leads for recommendations of appointments to the Board.

Audit Committee

The purpose of the Audit Committee is to ensure the Charity's annual accounts, budgets and plans are reflected accurately by management accounts and other financial reports presented to them by the finance team.

Remuneration Committee

The purpose of the Remuneration Committee is to provide assurance to the Board that the CCDC has an effective People and Pay Strategy in place which supports the delivery of the Strategy, promoting an effective, high performing and diverse workforce, and to oversee issues relating to the remuneration


of staff, with specific responsibility for making recommendations to the Board regarding the Remuneration Policy and the Executive's remuneration.

Risk Committee

The purpose of the Risk Committee is primarily to ensure that:

- risks to the business, assets and reputation of CCDC are identified, assessed and monitored;
- a risk management framework is created and implemented;
- a register of risks is maintained; and
- a disaster response strategy is in place.

The CCDC also has two wholly owned subsidiaries, CCDC Inc. and CCDC Services Limited with each holding one Board meeting per year with their Directors in April and May respectively.



Resonance (III)
By Clare Crouchman

Management and Staffing

The day-to-day management of the CCDC is delegated by the Board of Trustees to the CEO and operational management is supported by the Senior Leadership Management Team (SLMT) and other managers who, in 2020 were:

Chief Executive Officer

Jürgen Harter

Senior Research Fellow

Jason Cole

Head of Strategic Partnerships/Interim Head of Software Development (from 1 April 2020)

Ian Bruno

Head of Database

Suzanna Ward

Head of Finance

Bing-Bing Waterman

Head of Human Resources and Organisational Design

Maggie Brown

Head of Software Development

Mike Slade (Resigned 31 March 2020)

Director of Business Development

Jonathan Betts

General Manager CCDC Inc

Carmen Nitsche

These individuals are the key management personnel. They provide reports for the Board of Trustees in support of governance of the Charity and attend Board of Trustees meetings to present operational reports as well as position papers to address particular topics of interest.

Remuneration Policy

The Board of Trustees give their time freely and no trustee received remuneration in the year. Details of Trustees' expenses and related party transactions are disclosed in Note 11 to the

accounts. The Board of Trustees entrust the directing, controlling, running and operation of the Charity to the Chief Executive Officer who is supported by key management personnel. The pay of the senior staff is reviewed annually and increased in accordance with the company pay policy which is applicable to all CCDC staff and approved by the Board of Trustees as part of the Budget approval process. Furthermore, the remuneration committee oversees any of the recommended salary changes, or any other changes to the company pay policy, and discusses trends in line with up-to-date benchmarking data provided by HR.

Risk Management

The CCDC maintains a register of key risks to the organisation which covers the following areas:

- **Business:** Staffing, External Dependencies, External Threats, Reputation
- **Finance:** Revenue, Expenditure, Financial Fraud
- **Building:** Infrastructure, Fire, Lease
- **Compliance:** Health and Safety, Governance, GDPR
- **Data and IT:** Scientific Fraud, Protection of Data Assets, IT Infrastructure

Risk Register entries cover the likelihood and impact of risks occurring, the steps the organisation takes to mitigate these and areas where further action is required. Any actions required are factored into objectives for functional teams at the CCDC. During 2020, management of our Risk Register moved to a new platform that makes it easier for risks to be reviewed, updated and reported.

The Trustees have oversight of risks facing the organisation through the Board

Risk Committee which reviews the Risk Register at least once a year. The Senior Leadership and Management Team at the CCDC undertook a review of the organisation's risks towards the end of 2020. The next review will take place in the first half of 2021.

Going Concern

The fast spread of Covid-19 has had a profound impact on the global economy. All businesses have been affected in one way or another, whether directly or indirectly. CCDC is no exception to this. The CCDC's Board of Trustees and management team have been closely monitoring the situation since the beginning of the outbreak. CCDC's business model is diverse. Our users are spread across academic research institutions and large pharmaceutical companies. The database and its associated products are distributed globally, to over 80 countries worldwide. We rely primarily on renewal income (approximately 90%) from a core of subscribers who have continued to access the database over the long term (for decades). The database has become an integral part of research and business operations for such users. In the last couple of years, we have invested heavily into more digital transformation and IT infrastructure that have enabled working remotely to become as efficient as working from the office. Additionally, the products and services we provide can be delivered electronically. Consequently, the

nationwide lockdown has relatively little impact on our productivity and how we deliver our digital products and services.

Although our original plans for 2020 have been affected by COVID-19, we have been able to rapidly readjust our focus in response to the developing situation. 100% of the staff were working from home during the first lockdown. We are committed to do all we can to support our staff. We provided necessary equipment for home working, allowing reduced and flexible working hours to support staff with personal commitments. Managers frequently checked in with staff for their wellbeing and mental health. During 2020, CCDC has not furloughed any staff, nor taken advantage of any of the government support schemes.

At the date of writing, we have visibility of almost 90% of the budget target in revenue, which is higher than the total revenue achieved in 2020. This is a fortunate position to be in at this point in the year. Most of the licensees have already renewed their licences for this calendar year. Moreover, ongoing multi-year agreements with large industrial partners will further contribute to achieving the revenue target for the year. On the academic side, which comprises roughly 1/3 of revenue, it remains to be seen what impact Covid-19 has on universities around the globe, and their budgets – should this landscape be much negatively affected, then there could be downwards pressure on CCDC's revenue coming from the academic segment.

We have budgeted to expand the workforce and further advance our charitable goals. However, these costs are not committed and can be scaled back if necessary. We are closely monitoring our financial position by continuous review and timely reforecasting.

The CCDC has a healthy cash balance in the bank which is easily accessible. We do not anticipate having to withdraw from the investment fund this year.



We maintain confidence in the sustainability of the CCDC's business operations. Given the nature of CCDC's business model, revenues for the year appear to remain robust. Accompanied by continued productivity and the security afforded by CCDC's liquid asset holdings, it is our expectation that the CCDC will overcome the hardship Covid-19 brings in the coming months and even years.

Generally speaking, the topics of digital drug design and manufacture as well as structural chemistry research based on excellent data are likely to receive a

further boost through the heightened pressure to find novel cures faster, meaning there could be increased global demand for CCDC's products and offerings.


A similar argument can be made for additional opportunities for online based learning and teaching of structural chemistry, thereby boosting CCDC's education and outreach activities, given that students and academics around the world may have to work from home for a while, and this in some cases even being the new normal.

Looking into the Future

Looking into the mid-term future (2-3 years), the CCDC will endeavour to launch a modern, more user-friendly and adaptive website (incl. eCommerce platform and revamped knowledge portal). This new website will underpin all the interactions with the end users and community along with appropriate calls to action. This effort will help deliver and categorise any of the information and materials created from the last decades, plus host the new information in an organised, nicely navigable and searchable way for the next 10 years. This is important from a future-proofing point of view and to generally push optimal virtual ways of working along with more automation.

The CCDC is fortunate to have an excellent scientific advisory board (SAB). The constituency of the SAB was drawn from our existing user base with scientists who have demonstrated track records in their respective fields along with an interest in applying crystallographic knowledge. Over 2021 our internal scientists and new Head of Science will continue to work with and further optimise the operational running of the SAB. The SAB members are charged with the task of recommending, evaluating and reviewing scientific choices and proposals as to areas to target for future development at CCDC - thereby influencing and driving our scientific strategy.

Adding an operational function to the CCDC will address the need for progressing faster with our digital transformation by establishing best-practice business systems and going from status quo workflows and processes to new streamlined and much more automated and interconnected workflows and business processes. This will help to realise the planned growth by implementing operational excellence. With the new Head of Operations planned to join later in mid 2021, we will build up the area of quality control and



quality assurance, as well as establish a more formal project management process via a new project management office (PMO) - allowing us to better handle the growing complexity of our set of various projects.

We will continue to run the CCDC in growth mode in order to achieve more of our charitable aims faster, turning the CCDC into a more agile organisation with improved branding and raising awareness of our unique selling points and value proposition (a winning combination of high-quality data, excellent science, cutting-edge software, and vast expertise) - going from £7.2m top-line revenue (79 people) in 2020 to £10m revenue (100+ people) by end of 2023. We will focus on delivering excellent value with a sense of urgency to a growing set of existing and new customers, both in the biopharmaceutical / chemistry sectors and biotech / other industries (agrochemical, petrochemical, advanced materials).

Further building up the commercial function, including marketing, product management, channel management, partnerships and alliances and service delivery, will widen our reach, increase customer engagement and centricity, and enable this growth.

Any generated surplus from the resulting growth will be reinvested in advancing science, data accessibility and utility, better products and services experience (UX/UI), growing education and outreach efforts, and all our skilled people, systems, processes, to continuously optimise and scale up. This is done with the general goal of serving our end users and the wider international scientific community in the best possible, sustainable way over the coming years.

It is fairly clear from recent world events in relation to Covid-19, that structural chemistry has a crucial role to play in battling diseases, and as a community we need to be versatile in

our approaches to ensure rapid response. Digital drug design and manufacture as well as digital advanced materials design will have a big role to play; we believe the concept of doing things digitally first before any steps are taken in the lab will gain more traction in coming years, and this will drive a need for intuitive and user-friendly solutions that provide quick yet accurate recommendations and insights for end users.

We also expect that the world will change further, towards more remote working or generally a mixed economy (with regular hybrid ways of working); this is a great opportunity for the CCDC to push more digital ways of working as this is something our teams are already used to and we intend to pioneer this more by leading the way with data and software which is accessible from anywhere in the world via the cloud. These new practices and methods will underpin general future ways of working for the research community, academia (e.g. remote teaching and virtual education at scale), and the biopharmaceutical industry and other domains which have a clear and ongoing need for structural chemistry. CCDC will help to shape this future and staying true to our vision and mission to globally advance structural science based on high-quality, trusted big data and software, reaching an ever-growing end user community.

Image from CCDC Office
History of the CCDC



References and Administrative Details of the Charity, its Trustees and Advisors

For the year ended 31 December 2020

Trustees

Dr. D. Martinsen, Chair

Professor A. Bacchi, Vice Chair

Ms. J. N. Currano

Professor J. M. Goodman

Dr. J. P. Overington

Dr. M. Stahl (*Resigned 18 May 2020*)

Dr. Nigel Pitchford (*Appointed 18 May 2020*)

Professor Susan Bourne (*Appointed 18 May 2020*)

Company Secretary Mr C Knight
(*Resigned 28 February 2020*)

Company registered number 02155347

Charity registered number 800579

Registered office

12 Union Road
Cambridge
CB2 1EZ

Chief executive officer Dr. J. Harter

Independent auditors

Peters Elworthy & Moore
Chartered Accountants
Salisbury House
Station Road
Cambridge
CB1 2LA

Bankers

Barclays Bank Plc
Cambridge
CB2 3AA

Solicitors

Hewitsons LLP
Shakespeare House
42 Newmarket Road
Cambridge
CB5 8EP

Investment Advisers

Newton Investment Management
Limited
160 Queen Victoria Street
London
EC4V 4LA

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report including the Strategic Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DISCLOSURE OF INFORMATION TO AUDITORS

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditors are aware of that information.

Approved by order of the members of the board of Trustees on and signed on its behalf by:

DocuSigned by:

CE1F6128C11048C...

07 June 2021

David Martinsen

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE CAMBRIDGE CRYSTALLOGRAPHIC
DATA CENTRE**

OPINION

We have audited the financial statements of The Cambridge Crystallographic Data Centre (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2020 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 December 2020 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE CAMBRIDGE CRYSTALLOGRAPHIC
DATA CENTRE (CONTINUED)**

OTHER INFORMATION

The Trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Auditors' Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report including the Strategic Report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' Report and the Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report including the Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE CAMBRIDGE CRYSTALLOGRAPHIC
DATA CENTRE (CONTINUED)**

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with trustees and other management, and from our charitable knowledge and experience;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, Charities Act 2011, taxation legislation and data protection, anti-bribery and employment legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence;
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit; and
- we reviewed the minutes of Trustees' meetings to identify and references to non-compliances with laws and regulations.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE CAMBRIDGE CRYSTALLOGRAPHIC
DATA CENTRE (CONTINUED)**

knowledge of actual, suspected and alleged fraud; and

- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we;

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- we evaluated the assumptions and judgements used by management within significant accounting estimates and assessed whether these indicated evidence of management bias; and
- performed audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with relevant regulators such as the Charity Commission.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE CAMBRIDGE CRYSTALLOGRAPHIC
DATA CENTRE (CONTINUED)**

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Jayne Rowe (Senior Statutory Auditor)

for and on behalf of

Peters Elworthy & Moore

Chartered Accountants

Statutory Auditors

Salisbury House

Station Road

Cambridge

CB1 2LA

Date:

18 June 2021

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND
EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Note	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
INCOME FROM:					
Charitable activities	2	6,434,079	129,100	6,563,179	6,109,622
Other trading activities	4	472,427	-	472,427	288,693
Investments	5	131,924	-	131,924	186,058
TOTAL INCOME		7,038,430	129,100	7,167,530	6,584,373
EXPENDITURE ON:					
Charitable activities	6	6,446,889	182,347	6,629,236	7,495,242
TOTAL EXPENDITURE		6,446,889	182,347	6,629,236	7,495,242
NET INCOME/(EXPENDITURE) BEFORE NET (LOSSES)/GAINS ON INVESTMENTS					
		591,541	(53,247)	538,294	(910,869)
Net gains/(losses) on investments	13	(31,800)	-	(31,800)	803,157
NET INCOME/(EXPENDITURE)		559,741	(53,247)	506,494	(107,712)
Transfers between funds	18	(63,453)	63,453	-	-
NET MOVEMENT IN FUNDS		496,288	10,206	506,494	(107,712)
RECONCILIATION OF FUNDS:					
Total funds brought forward		7,049,156	13,919	7,063,075	7,170,787
Net movement in funds		496,288	10,206	506,494	(107,712)
TOTAL FUNDS CARRIED FORWARD		7,545,444	24,125	7,569,569	7,063,075

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 40 to 69 form part of these financial statements.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02155347

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2020

	Note	2020 £	2019 £
FIXED ASSETS			
Tangible assets	12	2,024,755	2,115,609
Investments	13	5,924,609	5,956,409
		<u>7,949,364</u>	<u>8,072,018</u>
CURRENT ASSETS			
Debtors	14	2,349,740	1,786,843
Cash at bank and in hand		3,199,162	2,038,311
		<u>5,548,902</u>	<u>3,825,154</u>
Creditors: amounts falling due within one year	15	(3,768,736)	(2,736,298)
NET CURRENT ASSETS		<u>1,780,166</u>	<u>1,088,856</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>9,729,530</u>	<u>9,160,874</u>
Creditors: amounts falling due after more than one year	16	(194,500)	(21,000)
Provisions for liabilities	17	(1,965,461)	(2,076,799)
TOTAL NET ASSETS		<u><u>7,569,569</u></u>	<u><u>7,063,075</u></u>
CHARITY FUNDS			
Restricted funds	18	24,125	13,919
Unrestricted funds	18	7,545,444	7,049,156
TOTAL FUNDS		<u><u>7,569,569</u></u>	<u><u>7,063,075</u></u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

David Martinsen

CE1F6128C11048C...

Date: 07 June 2021

David Martinsen

The notes on pages 40 to 69 form part of these financial statements.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02155347

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2020

	Note	2020 £	2019 £
FIXED ASSETS			
Tangible assets	12	2,023,868	2,113,375
Investments	13	6,088,098	6,119,898
		<u>8,111,966</u>	<u>8,233,273</u>
CURRENT ASSETS			
Debtors	14	2,761,044	1,826,090
Cash at bank and in hand		2,565,605	1,693,000
		<u>5,326,649</u>	<u>3,519,090</u>
Creditors: amounts falling due within one year	15	(3,838,352)	(2,728,384)
		<u>1,488,297</u>	<u>790,706</u>
NET CURRENT ASSETS			
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>9,600,263</u>	<u>9,023,979</u>
Creditors: amounts falling due after more than one year	16	(194,500)	(21,000)
Provisions for liabilities	17	(1,965,461)	(2,076,799)
		<u>7,440,302</u>	<u>6,926,180</u>
TOTAL NET ASSETS			
		<u>7,440,302</u>	<u>6,926,180</u>
CHARITY FUNDS			
Restricted funds	18	24,125	13,919
Unrestricted funds	18	7,416,177	6,912,261
		<u>7,440,302</u>	<u>6,926,180</u>
TOTAL FUNDS			
		<u>7,440,302</u>	<u>6,926,180</u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

David Martinsen

CE1F6128C11048C...

Date: 07 June 2021

David Martinsen

The notes on pages 40 to 69 form part of these financial statements.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	2020 £	2019 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net cash used in operating activities	20	1,071,413	(277,806)
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends, interests and rents from investments		131,924	186,058
Purchase of tangible fixed assets	12	(42,486)	(56,825)
NET CASH PROVIDED BY INVESTING ACTIVITIES		89,438	129,233
CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR		1,160,851	(148,573)
Cash and cash equivalents at the beginning of the year		2,038,311	2,186,884
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	21	3,199,162	2,038,311

The notes on pages 40 to 69 form part of these financial statements

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Cambridge Crystallographic Data Centre meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

1.2 COMPANY STATUS

The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

1.3 FUND ACCOUNTING

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES (CONTINUED)

1.4 BASIS OF CONSOLIDATION

The financial statements consolidate the accounts of The Cambridge Crystallographic Data Centre and all of its subsidiary undertakings ('subsidiaries'). The results of the subsidiaries are consolidated on a line by line basis.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements, however, note 18 of the accounts provides the funds movement of the company only.

The company reported a surplus for the period of £514,122 (2019 - deficit of £112,109).

1.5 GOING CONCERN

The Cambridge Crystallographic Data Centre meets its day to day working capital requirements through the cash it holds and generates. The charity undertakes a regular process of reviewing forecasts and projections to ensure that it has adequate resources for its continued operations and can draw on its investment portfolio to support its planned activities if required.

Management have reviewed the impact to date of the global COVID-19 pandemic on the operations of the charity and having considered a number of scenarios and mitigating actions in relation to the potential impact of the virus such that the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for at least 12 months. For this reason, the charity continues to adopt the going concern basis in preparing its financial statements.

1.6 INCOME

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Subscription income is recognised over the period to which it relates, with income being received in advance deferred.

Trading income, consisting of software and consultancy advice is recognised as supplied while maintenance and support services are recognised over the period to which they relate.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank. Dividends are recognised once the dividend had been declared and notification has been received of the dividend due.

1.7 EXPENDITURE

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

1. ACCOUNTING POLICIES (CONTINUED)

1.7 EXPENDITURE (CONTINUED)

Charitable activities and governance costs are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities based on staff roles and time.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.8 TANGIBLE FIXED ASSETS AND DEPRECIATION

All assets costing more than £10,000 are capitalised.

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities.

The cost of replacing and upgrading scientific computer equipment is written off as maintenance to scientific equipment in the income and expenditure account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Long-term leasehold property	- 2% straight line
Fixtures and fittings	- 25% reducing balance
Computer equipment	- 3-5 years straight line

1.9 INVESTMENTS

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated Statement of Financial Activities.

Investments in subsidiaries are valued at cost less provision for impairment.

1.10 DEBTORS

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 CASH AT BANK AND IN HAND

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES (CONTINUED)

1.12 LIABILITIES

Liabilities and provisions are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within support costs.

1.13 FINANCIAL INSTRUMENTS

The Group only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 TAXATION

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

1.15 FOREIGN CURRENCIES

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

1. ACCOUNTING POLICIES (CONTINUED)

1.16 PENSIONS

The Charity participates in the Universities Superannuation Scheme, a defined benefit scheme which is externally funded and contracted out of the State Earnings-related Pension Scheme. The fund is valued every three years by a professionally qualified independent actuary using the projected unit method, the rates of contribution payable being determined by the trustees on the advice of the actuary. In the intervening years, the actuary reviews the progress of the scheme. Pension costs are accounted for over the period during which the Charity benefits from the employees services.

The Charity also participates in the Cambridge University Assistants' Contributory Pension Scheme (CUACPS) which is a defined benefit scheme. The Charity's contributions are affected by a surplus or deficiency in the CUACPS but the Charity is unable to identify its share of the underlying assets and liabilities in the Scheme on a consistent and reasonable basis. The Charity therefore accounts for its contributions to the CUACPS as if it were a defined contribution scheme.

1.17 CRITICAL ACCOUNTING ESTIMATES AND AREAS OF JUDGEMENT

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgment:

FRS102 makes the distinction between a group pension plan and a multi-employer pension scheme. A group plan consists of a collection of entities under common control typically with a sponsoring employer. A multi-employer scheme is a scheme for entities not under common control and represents (typically) an industry-wide scheme such as that provided by USS. The accounting for a multi-employer scheme where the employer has entered into an agreement with the scheme that determines how the employer will fund a deficit results in the recognition of a liability for the contributions payable that arise from the agreement (to the extent that they relate to the deficit) and the resulting expense is recognised in profit or loss. The Executive Committee are satisfied that the scheme provided by USS meets the definition of a multi-employer scheme and has therefore recognised the discounted fair value of the contractual contributions under the funding plan in existence at the date of approving the financial statements.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

2. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Scientific Activity	6,434,079	129,100	6,563,179	6,109,622
TOTAL 2019	5,903,798	205,824	6,109,622	

Included within the above is a gift in kind, being free subventions amounting to £201,727 (2019 - £328,536).

3. TURNOVER

The whole of the turnover is attributable to the principal activities of the Charity.

A geographical split of turnover is disclosed as follows: United Kingdom 17% (2019 - 16%), Other EU 21% (2019 - 29%) and Rest of the World 62% (2019 - 55%)

4. INCOME FROM TRADING ACTIVITIES

Income from non charitable trading activities

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Trading subsidiary sales	472,427	472,427	288,693
TOTAL 2019	288,693	288,693	

The wholly owned trading subsidiary CCDCC Services Limited is incorporated in the United Kingdom and pays all of its profits to the charity under a deed of covenant. The summary financial performance of the subsidiary is shown in note 26.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

5. INVESTMENT INCOME

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Investment income	116,960	116,960	161,174
Bank & other interest receivable	14,964	14,964	24,884
	<u>131,924</u>	<u>131,924</u>	<u>186,058</u>
TOTAL 2019	<u>186,058</u>	<u>186,058</u>	

In 2019, all investment income was unrestricted.

6. ANALYSIS OF EXPENDITURE BY ACTIVITIES

	Activities undertaken directly 2020 £	Grant funding of activities 2020 £	Support costs 2020 £	Total funds 2020 £	Total funds 2019 £
Scientific Activities	5,329,896	243,337	1,056,003	6,629,236	7,495,242
TOTAL 2019	<u>6,134,408</u>	<u>75,645</u>	<u>1,285,189</u>	<u>7,495,242</u>	

In 2019, restricted expenditure amounted to £214,035 and unrestricted expenditure was £7,281,207.

Included within the above direct costs is a gift in kind, being free subventions amounting to £201,727 (2019 - £328,536).

Support costs include £11,493 related to delivering grant funding activities (2019 - £11,836).

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

7. DIRECT COSTS

	2020	2019
	£	£
Attendance at scientific meetings	32,116	247,380
Consultants	31,960	29,684
Difference of foreign exchange	61,949	67,993
Subvention subsidy	201,727	328,536
Research and Innovation cost - joint academic research projects	100,531	-
Legal and professional fees	578	2,350
Maintenance of scientific equipment	263,750	206,555
Production and distribution costs	96,600	103,842
Recruitment costs	-	87,673
Staff development	36,508	46,019
Wages and salaries	4,504,177	5,014,376
	5,329,896	6,134,408

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

8. SUPPORT COSTS

	2020	2019
	£	£
Audit and accountancy	36,738	35,687
Bad debt expense	491	167
Banking costs	2,759	3,022
Consultants	25,736	37,152
Depreciation	133,342	126,798
Difference on Foreign exchange - Support	(92,030)	51,919
Finance cost of unwinding of discounting	(111,338)	34,296
General expenses	37,918	82,158
Insurance	48,649	48,202
IT equipment, software and hardware	15,041	9,031
Legal and other professional fees	25,780	47,572
Recruitment costs	96,502	4,266
Premises costs	200,052	254,647
Staff development	13,510	30,100
Telephone and network costs	5,832	5,761
Wages and salaries	617,021	514,411
	1,056,003	1,285,189

During the year ended 31 December 2020, the company incurred the following Governance costs:

Board expenses £NIL (2019 - £24,700) and audit fees £15,325 (2019 - £13,650).

9. ANALYSIS OF GRANTS

	Grants to Institutions 2020	Total funds 2020	Total funds 2019
	£	£	£
Grants	243,337	243,337	75,645
TOTAL 2019	75,645	75,645	

The Group has made the following material grants to institutions during the year:

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

9. ANALYSIS OF GRANTS (CONTINUED)

	2020	2019
	£	£
NAME OF INSTITUTION		
University of Oxford	-	8,438
University of Leeds	8,000	32,000
University of Cambridge	53,966	7,500
University of Southampton	-	6,000
University of Liverpool	34,000	7,500
University of Manchester	-	6,667
University of Strathclyde	30,000	-
University of Sheffield	30,000	-
University of Edinburgh	37,874	-
University of Durham	48,000	-
Other immaterial grant costs	1,497	7,540
	243,337	75,645
	243,337	75,645

10. NET INCOME/(EXPENDITURE)

	2020	2019
	£	£
Auditors' remuneration - audit	15,325	13,650
Depreciation of tangible fixed assets:		
- owned by the charitable group	133,340	126,866

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

11. STAFF COSTS, KEY MANAGEMENT PERSONNEL AND TRUSTEES' REMUNERATION AND EXPENSES

Staff costs were as follows:

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Wages and salaries	3,943,208	3,468,821	3,612,868	3,160,271
Social security costs	448,381	389,372	377,358	319,095
Other pension costs	726,700	1,704,890	693,096	1,676,902
	5,118,289	5,563,083	4,683,322	5,156,268

The average number of persons employed by the Charity during the year was as follows:

	Group 2020 No.	Group 2019 No.	Charity 2020 No.	Charity 2019 No.
Office and Administration	8	8	7	8
Technical	69	56	65	56
	77	64	72	64

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2020 No.	Group 2019 No.
In the band £60,001 - £70,000	9	9
In the band £70,001 - £80,000	8	6
In the band £80,001 - £90,000	4	3
In the band £90,001 - £100,000	-	1
In the band £100,001 - £110,000	-	1
In the band £120,001 - £130,000	1	-
In the band £140,001 - £150,000	1	-

The key management personnel of the charity comprise the trustees, the Chief Executive Officer and the Senior Leadership Management Team. No trustees received any remuneration or benefits in kind from the charity (2019 - £NIL). The total employee benefits of the key management personnel, including employers' NIC and employers pension of the charity were £990,426 (2019 - £1,000,946).

A total of £nil (2019 - £8,386) was reimbursed or paid directly to 0 (2019 - 7) trustees in respect of travel and accommodation costs.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

12. TANGIBLE FIXED ASSETS

GROUP

	Long-term leasehold property £	Fixtures and fittings £	Total £
COST OR VALUATION			
At 1 January 2020	3,950,387	708,894	4,659,281
Additions	15,868	26,618	42,486
Disposals	-	(2,915)	(2,915)
At 31 December 2020	<u>3,966,255</u>	<u>732,597</u>	<u>4,698,852</u>
DEPRECIATION			
At 1 January 2020	1,996,637	547,035	2,543,672
Charge for the year	79,034	54,306	133,340
On disposals	-	(2,915)	(2,915)
At 31 December 2020	<u>2,075,671</u>	<u>598,426</u>	<u>2,674,097</u>
NET BOOK VALUE			
At 31 December 2020	<u><u>1,890,584</u></u>	<u><u>134,171</u></u>	<u><u>2,024,755</u></u>
At 31 December 2019	<u><u>1,953,750</u></u>	<u><u>161,859</u></u>	<u><u>2,115,609</u></u>

CHARITY

	Long-term leasehold property £	Fixtures and fittings £	Total £
COST OR VALUATION			
At 1 January 2020	3,950,387	704,842	4,655,229
Additions	15,868	26,618	42,486
Disposals	-	(2,915)	(2,915)
At 31 December 2020	<u>3,966,255</u>	<u>728,545</u>	<u>4,694,800</u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

12. TANGIBLE FIXED ASSETS (CONTINUED)

CHARITY (CONTINUED)

	Long-term leasehold property £	Fixtures and fittings £	Total £
DEPRECIATION			
At 1 January 2020	1,996,637	545,217	2,541,854
Charge for the year	79,034	52,959	131,993
On disposals	-	(2,915)	(2,915)
At 31 December 2020	<u>2,075,671</u>	<u>595,261</u>	<u>2,670,932</u>
NET BOOK VALUE			
At 31 December 2020	<u>1,890,584</u>	<u>133,284</u>	<u>2,023,868</u>
At 31 December 2019	<u>1,953,750</u>	<u>159,625</u>	<u>2,113,375</u>

13. FIXED ASSET INVESTMENTS

Group	Listed investments £
COST OR VALUATION	
At 1 January 2020	5,956,409
Revaluations	(31,800)
AT 31 DECEMBER 2020	<u>5,924,609</u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

13. FIXED ASSET INVESTMENTS (CONTINUED)

All the listed fixed asset investments are held in the UK.

All investments are carried at their fair value. Investments in equities and fixed interest securities are all traded in quoted public markets, primarily the London Stock Exchange. Holdings in common investment funds, unit trusts and open-ended investment companies are at bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The Charity does not make use of derivatives and similar complex financial instruments as it takes the view that investments are held for long term growth and annual income.

The Group has no material investment holdings in markets subject to exchange controls or trading restrictions.

Charity	Investments in subsidiary companies £	Listed investments £	Total £
COST OR VALUATION			
At 1 January 2020	163,489	5,956,409	6,119,898
Revaluations	-	(31,800)	(31,800)
AT 31 DECEMBER 2020	163,489	5,924,609	6,088,098

14. DEBTORS

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
DUE WITHIN ONE YEAR				
Trade debtors	2,035,220	1,507,896	1,899,268	1,330,464
Amounts owed by group undertakings	-	-	582,851	251,462
Other debtors	135,461	51,463	130,427	51,461
Prepayments and accrued income	179,059	227,484	148,498	192,703
	2,349,740	1,786,843	2,761,044	1,826,090

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Trade creditors	57,564	61,754	56,839	60,714
Amounts owed to group undertakings	-	-	169,533	126,687
Other taxation and social security	218,251	139,274	175,767	112,978
Other creditors	160,252	78,120	160,252	78,120
Accruals and deferred income	3,332,669	2,457,150	3,275,961	2,349,885
	3,768,736	2,736,298	3,838,352	2,728,384
	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Deferred income at 1 January 2020	2,305,300	3,087,601	2,210,436	3,022,601
Resources deferred during the year	3,248,874	2,305,300	3,202,083	2,210,436
Amounts released from previous periods	(2,305,300)	(3,087,601)	(2,210,436)	(3,022,601)
Deferred income at 31 December 2020	3,248,874	2,305,300	3,202,083	2,210,436

Deferred income relates to subscriptions received in advance.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

16. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Other creditors	194,500	21,000	194,500	21,000

Other creditors relate to grant commitments due after more than one year.

17. PROVISIONS

Group and Charity

	Pension deficit funding provision £
At 1 January 2020	2,076,799
Additions	(111,338)
	1,965,461

PENSION DEFICIT FUNDING PROVISION

The Charity participates in the University Superannuation Scheme (USS), a multi-employer defined benefit scheme. The charity is making additional contributions to address the funding deficit of the scheme and in accordance with FRS102 provision has been made for the future funding requirement. A discount factor of 0.73% (2019 - 1.68%) has been applied to future contributions and the liability represents the present value of the contributions payable. The provision has been valued using BUFDG – Guidance regarding discount rate for institutions participating in USS.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2020 £
UNRESTRICTED FUNDS						
DESIGNATED FUNDS						
Fixed Asset Fund	2,115,609	-	-	(90,854)	-	2,024,755
Research and Development Fund	173,406	-	-	-	-	173,406
Scientific Travel Fund	16,011	-	-	(16,011)	-	-
Sponsorship and Outreach Fund	153,326	-	(243,337)	166,011	-	76,000
CSD and Sustainability Fund	100,086	-	-	-	-	100,086
Pension Provision Fund	-	-	-	744,000	-	744,000
	<u>2,558,438</u>	<u>-</u>	<u>(243,337)</u>	<u>803,146</u>	<u>-</u>	<u>3,118,247</u>
GENERAL FUNDS						
General Funds - all funds	4,490,718	7,038,430	(6,203,552)	(866,599)	(31,800)	4,427,197
TOTAL UNRESTRICTED FUNDS	<u>7,049,156</u>	<u>7,038,430</u>	<u>(6,446,889)</u>	<u>(63,453)</u>	<u>(31,800)</u>	<u>7,545,444</u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. STATEMENT OF FUNDS (CONTINUED)

RESTRICTED FUNDS

BBSRC Student grant fund	13,919	29,049	(18,843)	-	-	24,125
DDA Grant	-	77,609	(129,349)	51,740	-	-
DIDCOM Grant	-	16,414	(27,356)	10,942	-	-
BioChem GRAPH	-	6,028	(6,799)	771	-	-
	<u>13,919</u>	<u>129,100</u>	<u>(182,347)</u>	<u>63,453</u>	<u>-</u>	<u>24,125</u>
TOTAL OF FUNDS	<u><u>7,063,075</u></u>	<u><u>7,167,530</u></u>	<u><u>(6,629,236)</u></u>	<u><u>-</u></u>	<u><u>(31,800)</u></u>	<u><u>7,569,569</u></u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. STATEMENT OF FUNDS (CONTINUED)

STATEMENT OF FUNDS - PRIOR YEAR

	Balance at 1 January 2019 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2019 £
UNRESTRICTED FUNDS						
DESIGNATED FUNDS						
Fixed Asset Fund	2,185,650	-	-	(70,041)	-	2,115,609
Research and Development Fund	173,406	-	-	-	-	173,406
Scientific Travel Fund	16,011	-	-	-	-	16,011
Sponsorship and Outreach Fund	225,190	-	(71,864)	-	-	153,326
CSD and Sustainability Fund	100,086	-	-	-	-	100,086
	<u>2,700,343</u>	<u>-</u>	<u>(71,864)</u>	<u>(70,041)</u>	<u>-</u>	<u>2,558,438</u>
GENERAL FUNDS						
General Funds - all funds	4,408,319	6,378,549	(7,209,343)	73,273	803,157	4,453,955
Foreign Exchange Reserve	46,705	-	-	(9,942)	-	36,763
	<u>4,455,024</u>	<u>6,378,549</u>	<u>(7,209,343)</u>	<u>63,331</u>	<u>803,157</u>	<u>4,490,718</u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. STATEMENT OF FUNDS (CONTINUED)

STATEMENT OF FUNDS - PRIOR YEAR (CONTINUED)

	Balance at 1 January 2019 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2019 £
TOTAL UNRESTRICTED FUNDS	7,155,367	6,378,549	(7,281,207)	(6,710)	803,157	7,049,156
RESTRICTED FUNDS						
Client Research Project	4,279	69,570	(73,307)	(542)	-	-
ADDoPT Project	3,243	105,580	(116,075)	7,252	-	-
BBSRC	7,898	30,674	(24,653)	-	-	13,919
	15,420	205,824	(214,035)	6,710	-	13,919
TOTAL OF FUNDS	7,170,787	6,584,373	(7,495,242)	-	803,157	7,063,075

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. STATEMENT OF FUNDS (CONTINUED)

STATEMENT OF FUNDS - CHARITY ONLY

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers in/out £	Gains/ (losses) £	2020 £
Designated funds (as detailed above)	2,558,438	-	(242,363)	803,146	-	3,119,221
General funds	4,353,823	7,029,381	(6,187,849)	(866,599)	(31,800)	4,296,956
Restricted funds (as detailed above)	13,919	129,100	(182,347)	63,453	-	24,125
Total	6,926,180	7,158,481	(6,612,559)	-	(31,800)	7,440,302

STATEMENT OF FUNDS - CHARITY ONLY - PRIOR YEAR

	Balance at 1 January 2019 £	Income £	Expenditure £	Transfers in/out £	Gains/ (losses) £	2019 £
Designated funds (as detailed above)	2,700,343	-	(71,864)	(70,041)	-	2,558,438
General funds	4,322,523	5,563,648	(6,398,836)	63,331	803,157	4,353,823
Restricted funds (as detailed above)	15,420	205,824	(214,035)	6,710	-	13,919
Total	7,038,286	5,769,472	(6,684,735)	-	803,157	6,926,180

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

STATEMENT OF FUNDS (CONTINUED)

The purpose of funds above are detailed as follows:

- **Fixed Asset Fund:** This fund represents the balance of the groups' reserves held as fixed assets. The transfer represents movements to fixed assets in the year.
- **Research and Development Fund:** This fund finances research activities and makes grants for research where general funds are not available for this purpose.
- **Sponsorship and Outreach Fund:** This fund supports the cost of funding studentships worldwide.
- **CSD and Sustainability Fund:** This fund is established to provide support in the event of unexpected legal, legislative or regulatory events which might have a negative effect on the Centre.
- **Scientific Travel Fund:** This fund meets travel costs of non-staff members furthering the CCDC's objectives. The balance of this fund was transferred into Sponsorship and Outreach Fund to provide support to students worldwide.
- **Pension Provision Fund:** a designated fund set up to provide provision to cover the deficit in the pension scheme.

Restricted Funds:

- **BBSRC:** This is a four year training grant funded by the BBSRC for research in global analysis of pharmacophoric space. It covers the period of 1 October 2016 to 30 September 2020.
- **DDA Grant:** The Digital Design Accelerator Platform is an InnovateUK funded project to develop digital risk assessments for pharmaceutical manufacturing processes. A collaboration between innovators, industry, and academia, this 24 month project is intended to build from recent advances in Digital Design methods. It provides us with industrial direction for research and development into Particle Informatics and the new CSD-Particle Suite. The project started on 1 March 2020.
- **BioChemGRAPH:** The BioChemGRAPH project aims to establish a collaboration between PDBe, ChEMBL and CCDC to create an easily accessible resource that integrates structural, functional and biochemical annotations of small molecule data into one place. This project will promote interoperability between small molecule resources by implementing common data standards. The project also aims to improve the findability and accessibility of small molecule annotations via uniform data access mechanisms and develop intuitive web components to visualise these valuable data through web interfaces. It will significantly increase the synergies between structural and biochemical data and will lead to increased understanding of the role of small molecules in biological systems and translational research in a number of areas, including synthetic biology, target validation, and drug development. The project started on 2 November 2020 and will last 36 months. BioChemGRAPH was 80% funded by BBSRC, 20% of the costs will be covered by the general fund.
- **DIDCOM:** The Digital Design of Complex Materials for Formulated Products (DIDCOM-FP) grant was awarded through the UKRI's Industry Strategy Challenge Fund (ISCF) Manufacturing Made Smarter Challenge. It is a collaborative project with industrial partners, that started in July 2020, centred on materials modelling. Our involvement is focused on solid-liquid equilibria and aims to create a database to enable better solubility prediction and solvent selection tools. This project will last 24 months.

DDA, DIDCOM projects are funded by InnovateUK. However, the grant only covers 60% of the costs. 40% will be funded by the general fund.

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

19. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT PERIOD

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	2,024,755	-	2,024,755
Fixed asset investments	5,924,609	-	5,924,609
Current assets	5,524,777	24,125	5,548,902
Creditors due within one year	(3,768,736)	-	(3,768,736)
Creditors due in more than one year	(194,500)	-	(194,500)
Provisions for liabilities and charges	(1,965,461)	-	(1,965,461)
TOTAL	7,545,444	24,125	7,569,569

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR PERIOD

	Unrestricted funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Tangible fixed assets	2,115,609	-	2,115,609
Fixed asset investments	5,956,409	-	5,956,409
Current assets	3,811,235	13,919	3,825,154
Creditors due within one year	(2,736,298)	-	(2,736,298)
Creditors due in more than one year	(21,000)	-	(21,000)
Provisions for liabilities and charges	(2,076,799)	-	(2,076,799)
TOTAL	7,049,156	13,919	7,063,075

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

ANALYSIS OF NET ASSETS BETWEEN FUNDS (CONTINUED)

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CHARITY ONLY - CURRENT YEAR

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	2,023,868	-	2,023,868
Fixed asset investments	6,088,098	-	6,088,098
Current assets	5,302,524	24,125	5,326,649
Creditors due within one year	(3,838,352)	-	(3,838,352)
Creditors due in more than one year	(194,500)	-	(194,500)
Provisions for liabilities and charges	<u>(1,965,461)</u>	<u>-</u>	<u>(1,965,461)</u>
Total	<u>7,416,177</u>	<u>24,125</u>	<u>7,440,302</u>

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CHARITY ONLY - PRIOR YEAR

	Unrestricted funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Tangible fixed assets	2,113,375	-	2,113,375
Fixed asset investments	6,119,898	-	6,119,898
Current assets	3,505,171	13,919	3,519,090
Creditors due within one year	(2,728,384)	-	(2,728,384)
Creditors due in more than one year	(21,000)	-	(21,000)
Provisions for liabilities and charges	<u>(2,076,799)</u>	<u>-</u>	<u>(2,076,799)</u>
Total	<u>6,912,261</u>	<u>13,919</u>	<u>6,926,180</u>

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

20. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	Group 2020 £	Group 2019 £
Net income/expenditure for the period (as per Statement of Financial Activities)	506,494	(107,712)
ADJUSTMENTS FOR:		
Depreciation charges	133,340	126,866
Gains/(losses) on investments	31,800	(803,157)
Dividends, interests and rents from investments	(131,924)	(186,058)
(Increase)/decrease in debtors	(562,833)	259,687
Increase/(decrease) in creditors	1,205,874	(717,320)
Movement in provisions	(111,338)	1,149,888
NET CASH PROVIDED BY/(USED IN) OPERATING ACTIVITIES	1,071,413	(277,806)

21. ANALYSIS OF CASH AND CASH EQUIVALENTS

	Group 2020 £	Group 2019 £
Cash in hand	3,199,162	2,038,311
TOTAL CASH AND CASH EQUIVALENTS	3,199,162	2,038,311

22. ANALYSIS OF CHANGES IN NET DEBT

	At 1 January 2020 £	Cash flows £	At 31 December 2020 £
Cash at bank and in hand	2,038,311	1,160,851	3,199,162
	2,038,311	1,160,851	3,199,162

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

23. PENSION COMMITMENTS

The Group operates a defined benefit pension scheme.

The Charity's employees belong to two principal pension schemes, the Universities Superannuation Scheme (USS) and the Cambridge University Assistants' Contributory Pension Scheme (CUACPS). The total pension cost for the period was £726,700 (2019 - £1,704,890).

Universities Superannuation Scheme

The Charity participates in the Universities Superannuation Scheme (USS), a defined benefit scheme which is contracted out of the State Second Pension (S2P). The assets of the scheme are held in a separate fund administered by the trustee, Universities Superannuation Scheme Limited.

The latest available complete actuarial valuation of the Retirement Income Builder is at 31 March 2018 (the valuation date), which was carried out using the projected unit method. A valuation as at 31 March 2020 is underway but not yet complete.

Since the institution cannot identify its share of USS Retirement Income Builder (defined benefit) assets and liabilities, the following disclosures reflect those relevant for those assets and liabilities as a whole.

The 2018 valuation was the fifth valuation for the scheme under the scheme-specific funding regime introduced by the Pensions Act 2004, which requires schemes to adopt a statutory funding objective, which is to have sufficient and appropriate assets to cover their technical provisions. At the valuation date, the value of the assets of the scheme was £63.7 billion and the value of the scheme's technical provisions was £67.3 billion indicating a shortfall of £3.6 billion and a funding ratio of 95%.

The key financial assumptions used in the 2018 valuation are described below. More detail is set out in the Statement of Funding Principles.

Pension increases (CPI)	Term dependent rates in line with the difference between the Fixed Interest and Index Linked yield curves, less 1.3% p.a.
Discount rate (forward rates)	Years 1-10: CPI + 0.14% reducing linearly to CPI – 0.73% Years 11-20: CPI + 2.52% reducing linearly to CPI + 1.55% by year 21 Years 21 +: CPI + 1.55%

The main demographic assumption used relates to the mortality assumptions. These assumptions are based on analysis of the scheme's experience carried out as part of the 2018 actuarial valuation. The mortality assumptions used in these figures are as follows:

	2018 valuation
Mortality base table	Pre-retirement: 71% of AMC00 (duration 0) for males and 112% of AFC00 (duration 0) for females Post retirement: 97.6% of SAPS S1NMA "light" for males and 102.7% of RFV00 for females
Future improvements to mortality	CMI_2017 with a smoothing parameter of 8.5 and a long term improvement rate of 1.8% pa for males and 1.6% pa for females

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

23. PENSION COMMITMENTS (CONTINUED)

Principal actuarial assumptions at the Balance Sheet date (expressed as weighted averages):

	At 31 December 2020 %	At 31 December 2019 %
Discount rate	2.59	2.44
Pensionable salary growth	n/a	n/a
Pension increases (CPI)	4.20	2.11

The current life expectancies on retirement at age 65 are:

	At 31 December 2020 Years	At 31 December 2019 Years
Males currently aged 65 (years)	24.4	24.6
Males currently aged 45 (years)	26.3	26.6
Females currently aged 65 (years)	25.9	26.1
Females currently aged 45 (years)	27.7	27.9

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

23. PENSION COMMITMENTS (CONTINUED)

Cambridge University Assistants' Contributory Pension Scheme

The Charity also participates in the Cambridge University Assistants' Contributory Pension Scheme (CUACPS) which is a defined benefit scheme. The Charity's contributions are affected by a surplus or deficiency in the CUACPS but the Charity is unable to identify its share of the underlying assets and liabilities in the Scheme on a consistent and reasonable basis. The Charity therefore accounts for its contributions to the CUACPS as if it were a defined contribution scheme.

The most recent full actuarial valuation of the CUACPS was carried out as at 31 July 2018 by an independent actuary, Robert Sweet, who is a Fellow of the Institute of Actuaries. He is not an employee or officer of the Charity. The CUACPS is not a closed scheme nor one in which the age profile of the active membership is rising significantly.

The method used in the actuarial valuation as at 31 July 2018 was the Projected Unit funding method. The main assumptions were:

Economic

Discount rate:	5.15%
Asset return for Recover Plan:	5.85%
Rate of Salary increases:	4.25%
Rate of increases in pensions in payment:	
- RPI max 12%, min 0%	3.25%
- RPI max 5%, min 0%	3.15%
- CPI max 5%, min 0%	2.25%
Rate of increases in pensions in deferment:	
- GMP	4.25%
- Pensions in excess of GMP:	
- RPI	3.25%
- CPI	2.25%

Assets & Expenses

Valuation of assets:	Surrender value of the assets
Expenses:	
- Past service	1.0% of the liability excluding expenses
- Future service	0.9% of the Pensionable Salary
Pension Protection Fund levies:	Included in the future service cost expense

Demographic

Rate of mortality:	121% of S2NMA pension mortality tables for males and 90% of S2NFA pension mortality tables for females. Plus a projection based upon the CMI_2017 model with a long term 1.25% p.a. improvement.
Assumed Age at Retirement:	
UNI 1	
- Active members	Males 63, Females 62
- Deferred members	Males 61, Females 61
UNI 2 & UNI 3	Males 65, Females 65
Proportion married	85%
Age difference	Women 3 years younger than their partners

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

23. PENSION COMMITMENTS (CONTINUED)

Value of benefits in respect of service on or before 31 July 2018:

Technical Provisions	[a]	£742,670,000
Market Value of Scheme Assets	[b]	£708,068,000
Past Service Surplus/(Deficit)	[b-a]	£34,602,000
Level of Funding of Past Service Benefit	[b]/[a]	95%

The Trustee and the University have agreed that Employer contributions should continue at the current rates. The Trustee and the University have also agreed that the Employer will continue to pay additional contributions of £14,595,000 p.a. from 1 August 2018 to 31 July 2020, which will eliminate the funding shortfall.

The ongoing overall joint contribution rate for future service benefits, ignoring the past service position, is 12.2% of Pensionable Salaries. The split of this rate is shown below:

Pre 2013 Members paying additional contributions under Rule 45.6

- 21.2% pa of Pensionable Salaries (Salary Sacrifice Members); and
- 12.7% pa of Pensionable Salaries (Other Members).

Other pre 2013 Members paying

- 17.7% pa of Pensionable Salaries (Salary Sacrifice Members); and
- 12.7% pa of Pensionable Salaries (Other Members).

Post 2013 Members

- 8.2% pa of Pensionable Salaries (Salary Sacrifice Members); and
- 5.2% pa of Pensionable Salaries (Other Members).

24. RELATED PARTY TRANSACTIONS

In 2020 the following transactions took place between the Charity and its wholly owned subsidiary CCDC Services Limited:

The provision of management services by the Charity to the company of £165,154 (2019: £155,816).

The transfer under deed of covenant of the trading profits of CCDC Services Limited to the Charity of £300,063 (2019: £104,929).

In 2020 the following transactions took place between the Charity and its wholly owned subsidiary CCDC Inc:

The provision of a sales office and related services by the company to the Charity of £511,211 (2019: £526,137).

There were no other outstanding balances with related parties as at 31 December 2020 (2019 - £NIL)

THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

25. INVESTMENT IN SUBSIDIARY COMPANIES

The Charity has a wholly owned subsidiary which is incorporated in the UK. CCDC Services Limited provides professional services in relation to digital drug design and manufacture, and advanced training. CCDC Services Limited transfers its taxable profits to The Cambridge Crystallographic Data Centre under a deed of covenant.

The Charity has a wholly owned subsidiary which is incorporated in the USA. CCDC Inc provides a sales office and administrative function for the charity within the US. All turnover in CCDC Inc arises from recharges to The Cambridge Crystallographic Data Centre. Therefore no amounts are disclosed within income from trading activities in the consolidated financial statements.

A summary of the results of CCDC Services Limited is shown in note 26.

26. PRINCIPAL SUBSIDIARIES

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Principal activity
CCDC Services Limited	03483374	12 Union Road, Cambridge, CB2 1EZ	Provision of professional services for digital drug design and manufacture, and advanced training.

Class of shares	Holding	Included in consolidation
Ordinary	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Profit/(Loss) / Surplus/ (Deficit) for the year £	Net assets £
CCDC Services Limited	472,428	(172,365)	300,036	2,118